Vicapsys Life Sciences

VICP

Biotechnology · Healthcare

Price

$1.46

+0.00 (+0.00%)

Market Cap

$47.3M

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+100.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 17.7M (2021) → 35.4M (2025)

Vicapsys Life Sciences is a small biotechnology company focused on developing drugs to treat cancer. Its research centers on compounds that target how cancer cells grow and spread, with the goal of eventually selling treatments to hospitals, oncologists, and patients. The company is in the early stage of drug development, meaning its products are not yet approved or sold commercially.

Vicapsys does not currently generate meaningful revenue, which is typical for early-stage biotech firms that spend years on research and clinical trials before earning any income. It operates primarily in the United States and has a very small market capitalization, reflecting the high uncertainty around its pipeline. The biggest risk the company faces is the long and expensive process of getting a drug approved by the FDA — most experimental drugs fail before reaching patients, and Vicapsys would likely need to raise additional capital to fund future trials.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+50.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$567/ year

↓ Declining (-96% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

43.1%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$5,876 cash & investments

Quarterly Free Cash Flow

Company generates more cash than it spends — no dilution risk from fundraising

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial